CoChat

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models

Open access
Maruggi, Giulietta, Mallett, Corey P., Westerbeck, Jason W., Chen, Tiffany, Lofano, Giuseppe, Friedrich, Kristian, Qu, Lin, Sun, Jennifer Tong, McAuliffe, Josie, Kanitkar, Amey, Arrildt, Kathryn T., Wang, Kai-Fen, McBee, Ian, McCoy, Deborah, Terry, Rebecca, Rowles, Alison, Abrahim, Maia Araujo, Ringenberg, Michael A., Gains, Malcolm J., Spickler, Catherine, Xie, Xuping, Zou, Jing, Shi, Pei-Yong, Dutt, Taru, Henao-Tamayo, Marcela, Ragan, Izabela, Bowen, Richard A., Johnson, Russell, Nuti, Sandra, Luisi, Kate, Ulmer, Jeffrey B., Steff, Ann-Muriel, Jalah, Rashmi, Bertholet, Sylvie, Stokes, Alan H., Yu, Dong · 2022 · Molecular Therapy
Cited by 88

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans, and the technology is being leveraged for rapid emergency response. In this report, we assessed immunogenicity and, for the first time, toxicity, biodistribution, and protective efficacy in preclinical models of a two-dose self-amplifying messenger RNA (SAM) vaccine, encoding a prefusion-stabilized spike antigen of SARS-CoV-2 Wuhan-Hu-1 strain and delivered by lipid nanoparticles (LNPs). In mice, one immunization with the SAM vaccine elicited a robust spike-specific antibody response, which was further boosted by a second immunization, and effectively neutralized the matched SARS-CoV-2 Wuhan strain as well as B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta) variants. High frequencies of spike-specific germinal center B, Th0/Th1 CD4, and CD8 T cell responses were observed in mice. Local tolerance, potential systemic toxicity, and biodistribution of the vaccine were characterized in rats. In hamsters, the vaccine candidate was well-tolerated, markedly reduced viral load in the upper and lower airways, and protected animals against disease in a dose-dependent manner, with no evidence of disease enhancement following SARS-CoV-2 challenge. Therefore, the SARS-CoV-2 SAM (LNP) vaccine candidate has a favorable safety profile, elicits robust protective immune responses against multiple SARS-CoV-2 variants, and has been advanced to phase 1 clinical evaluation (NCT04758962).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2022.01.001

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 88

Metadata

Authors
Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J. T., McAuliffe, J., Kanitkar, A., Arrildt, K. T., Wang, K.-F., McBee, I., McCoy, D., Terry, R., Rowles, A., Abrahim, M. A., Ringenberg, M. A., Gains, M. J., Spickler, C., Xie, X., Zou, J., Shi, P.-Y., Dutt, T., Henao-Tamayo, M., Ragan, I., Bowen, R. A., Johnson, R., Nuti, S., Luisi, K., Ulmer, J. B., Steff, A.-M., Jalah, R., Bertholet, S., Stokes, A. H., & Yu, D.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2022-05
Volume
30
Issue
5
Pages
1897-1912
ISSN
1525-0016 (ISSN-L)
OpenAlex
W4206756749
Cited by
88
References
22
FWCI
8.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. https://app.cochat.ai/papers/10.1016/j.ymthe.2022.01.001
The paper
Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J. T., McAuliffe, J., Kanitkar, A., Arrildt, K. T., Wang, K.-F., McBee, I., McCoy, D., Terry, R., Rowles, A., Abrahim, M. A., Ringenberg, M. A., Gains, M. J., . . . Yu, D. (2022). A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2022.01.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.